Chronic mucocutaneous candidiasis: what can we conclude about IL-17 antagonism?

Purpose: IL-17 antagonists are effective for psoriasis in clinical trials, but long-term safety is not fully characterized. Since chronic mucocutaneous candidiasis (CMC) is caused by defects in the IL-17 pathway, CMC risk data have been touted as providing reassurance about the safety of IL-17 antag...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of dermatological treatment 2018-07, Vol.29 (5), p.475-480
Main Authors: Veverka, Kevin K., Feldman, Steven R.
Format: Article
Language:English
Subjects:
chronic mucocutaneous candidiasis
esophageal cancer
IL-17
oropharyngeal cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: IL-17 antagonists are effective for psoriasis in clinical trials, but long-term safety is not fully characterized. Since chronic mucocutaneous candidiasis (CMC) is caused by defects in the IL-17 pathway, CMC risk data have been touted as providing reassurance about the safety of IL-17 antagonism. Methods: We performed a literature review to identify patients with CMC and compared the prevalence of cancer in these patients to the reported 5-year prevalence. Results: There was a higher prevalence of oropharyngeal (2.5% vs. 0.028%; p 
ISSN:0954-6634
1471-1753
DOI:10.1080/09546634.2017.1398396